AUTHOR INDEX

Abuchowski, A., 139
Artursson, P., 25
Audus, K.L., 51

Bae, Y.H., 167, 255
Bagniefski, T., 113
Barshun, C.L., 3
Berner, B., 105
Burnette, R.R., 113
Burton, P.S., 3

Caplan, A.I., 157
Cremers, H.F.M., 167
Crommelin, D.J.A., 233

Danilov, S.M., 297
Daoud, S.S., 225
Day, J.S., 3
de Jong, W.H., 233
DeNuzzio, J.D., 105
Dice, J.F., 25
Dix, C.J., 25

Eldridge, J.H., 205
Eling, W.M.C., 233

Feijen, J., 167
Firestone, B.A., 181
Fleisher, D., 41
Fuertges, F., 139
Fujita, T., 149

Genka, S., 61
Gilley, R.M., 205
Gleeson, J.M., 193
Golomb, G., 245
Good, W.R., 315
Greig, N.H., 61

Hammond, C.J., 205
Hashida, M., 149
Hassan, I.F., 25
Ho, N.F.H., 3
Holmberg, D.L., 193

Inoue, S., 269

Jacobs, H., 255
John, V.A., 307
Johnston, T.P., 245
Jong, W.H. de, 233
Juliano, R.L., 225

Kataoka, K., 269
Khaw, B.A., 297
Kim, S.W., 167, 193, 255
Klibanov, A.L., 297
Knutson, K., 93
Kondo, T., 215
Kopeček, J., 279
Krill, S.L., 93
Kwon, G., 167

Lattin, G.A., 123
Lee, V.H.L., 79
Levitsky, D.O., 297
Levy, R.J., 245
Lippert, C.L., 41

Mack, E.J., 193
Mackay, M., 25
Makino, K., 193
Mazer, N.A., 343
McVie, J.G., 167
Meulbroek, J.A., 205
Miyauchi, M., 269

Nässander, U.K., 233
Noteborn, H.P.J.M., 167

Okano, T., 255, 269
Olanoff, L.S., 331

Padmanabhan, R.V., 123
Pai, C.M., 193
Peeters, P.A.M., 233
Phipps, J.B., 123
Piraino, A.J., 315
Pollock, S.R., 331

Rapoport, S.I., 61
Raub, T.J., 3
Reppas, C., 41

Sakurai, Y., 269
Sawchuk, R.J., 123
Seminoff, L.A., 193
Sezaki, H., 149
Shah, R., 25
Sheth, N., 41
Siegel, R.A., 181
Sintov, A., 245
Slinkin, M.A., 297
Staas, J.K., 205
Steerenberg, P.A., 233
Storm, G., 233

Takakura, Y., 149
Tice, T.R., 205
Torchilin, V.P., 297

Williamson, I., 25
Wilson, D.E., 193
Wilson, G., 25
Wlodyga, J., 41

Yamada, N., 269
Yasuda, Y., 149
Yokoyama, M., 269

Zhang, J., 93

SUBJECT INDEX

absorption mechanisms, 3
ACE inhibitor, 315
adriamycin, 167, 269
albumin–heparin conjugate, 167
aminopeptidase, 51
angiotensin, 51, 315
angiotensin–renin system, 315
antibodies, 297
antitumor drug delivery, 225, 233
arrhythmia, 245

β-adrenoceptor blocking drugs, 302
bioadhesive polymers, 279
biotin–avidin complex, 297
block copolymers, 269
blood–brain barrier, 51, 61
bone repair, 157
brain tumor treatment, 61
buccal absorption, 3

Caco-2 cells, 3, 25
calcification, 245
calcium–drug interaction, 41
cancer chemotherapy, 61, 225, 233, 269
capsule size-dependent permeability, 215
cell delivery, 157
cell line, 25
cell model, 25
chelating polymers, 297
chemical modification, 139
chemoembolization, 167
chlorambucil, 61
clinical pharmacology, 331
composite microcapsule membrane, 215
concanavalin A competitive binding, 193
controlled release implants, 245
crosslinked gel, 193

dextran conjugation, 149
diabetes, 181
drug–nutrient interaction, 41
drug targeting, 233

endocytosis, 51

glucose–drug interaction, 41
glycosylated insulins, 193

hydromorphone, 123
hydrophilic nylon microcapsules, 193
N-(2-hydroxypropyl)methacrylamide copolymers, 279

immunogenicity, 139
immunoliposomes, 233
impedance, 113
impedance spectroscopy, 105
infusion pump, 331
input function, 343
insulin pump, 181
interpenetrating polymer networks, 255
intestinal absorption, 3, 41
intestinal epithelial, 25
intranasal drug delivery, 331
in vivo studies, 123
ion-exchange hydrogels, 167
ionophores, 225
ion-pair formation, 79
ion selectivity, 105
iontophoresis, 105, 113, 123
ion transport, 105, 113

liposomes, 225, 233
lysosomes, 291

macromolecular carrier, 149
malaria chemotherapy, 233
marrow, 157
metoprolol fumarate, 307
micelles, 269
microcapsule membrane, 215
microspheres, 167, 205
mitomycin C–dextran conjugate, 149
modelling, 343
modulated drug delivery, 255

narcotic, 123

ocular drug delivery, 93
oral controlled release, 205, 331
OROS system, 307
oscillatory solute permeation, 215

pacemaker, 245
paracellular pathway, 79
penetration enhancers, 79, 93
peptide absorption, 3
peptide sequences, 291
peptide transport, 51
permeability characteristics, 215
Peyer's patch, 3, 205
pharmacodynamics, 315, 343
pharmacokinetics, 139, 149, 343

pharmacology, 315
phenytoin, 41
photodynamic therapy, 279
pH-sensitive hydrogels, 181
poly(ethylene glycol), 139
poly(*N*)-isopropylacrylamide), 255
polymeric drugs, 269
polypeptides, 343
porous ceramic, 157
prodrugs, 61, 79
protein degradation, 291
proteins, 139
protein targeting, 291

radioimmunoimaging, 297

self-regulating insulin delivery system, 181, 193
site-specific 5-aminosalicylic acid delivery, 279
sleep-inducing peptide, 51
stem cells, 157
stratum corneum, 93
sustained release preparation, 245
swelling, 181, 255

targetable polymeric drug carriers, 279
thermosensitive hydrogels, 255
thermotropic phase behavior, 93
transcellular pathway, 79
transdermal drug delivery, 93, 105, 113, 123

uricase–dextran conjugate, 149

vaccine, 205